Eledon Pharmaceuticals Inc
NASDAQ:ELDN
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
1.12
5.3
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one ELDN stock under the Base Case scenario is 2.1082 USD. Compared to the current market price of 4.0677 USD, Eledon Pharmaceuticals Inc is Overvalued by 48%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Eledon Pharmaceuticals Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for ELDN cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Eledon Pharmaceuticals Inc
Balance Sheet Decomposition
Eledon Pharmaceuticals Inc
Current Assets | 87.2m |
Cash & Short-Term Investments | 83.6m |
Other Current Assets | 3.6m |
Non-Current Assets | 33.3m |
PP&E | 621k |
Intangibles | 32.4m |
Other Non-Current Assets | 255k |
Current Liabilities | 6m |
Accounts Payable | 2.1m |
Accrued Liabilities | 3.9m |
Non-Current Liabilities | 123m |
Other Non-Current Liabilities | 123m |
Earnings Waterfall
Eledon Pharmaceuticals Inc
Revenue
|
0
USD
|
Operating Expenses
|
-46.9m
USD
|
Operating Income
|
-46.9m
USD
|
Other Expenses
|
-41.6m
USD
|
Net Income
|
-88.5m
USD
|
Free Cash Flow Analysis
Eledon Pharmaceuticals Inc
USD | |
Free Cash Flow | USD |
ELDN Profitability Score
Profitability Due Diligence
Eledon Pharmaceuticals Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
Score
Eledon Pharmaceuticals Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
ELDN Solvency Score
Solvency Due Diligence
Eledon Pharmaceuticals Inc's solvency score is 53/100. The higher the solvency score, the more solvent the company is.
Score
Eledon Pharmaceuticals Inc's solvency score is 53/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ELDN Price Targets Summary
Eledon Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for ELDN is 14.28 USD with a low forecast of 7.07 USD and a high forecast of 29.4 USD.
Dividends
Current shareholder yield for ELDN is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people requiring an organ or cellular transplant, and for people living with autoimmune and neurodegenerative disease. The company is headquartered in Irvine, California and currently employs 12 full-time employees. The company went IPO on 2014-09-17. The firm is focused on developing targeted medicines for persons requiring an organ or cell-based transplant, living with autoimmune disease, or living with amyotrophic lateral sclerosis (ALS). Its lead compound in development is AT-1501, an IgG1, anti-CD40L antibody with high affinity for the CD40 Ligand (CD40L, also called CD154). AT-1501 is engineered to improve both safety and provide pharmacokinetic, pharmacodynamic, and dosing advantages compared to other anti-CD40 approaches. Blocking CD40L inhibits both CD40 and CD11 costimulatory signaling pathways with the potential for better efficacy. The company is focused on developing AT-1501 in up to four indications: ALS, prevention of kidney allograft rejection, prevention of islet cell allograft rejection, and IgA Nephropathy (IgAN). The company has completed a Phase Ia/Ib single ascending dose trial in volunteers and people with amyotrophic lateral sclerosis (ALS).
Contact
IPO
Employees
Officers
The intrinsic value of one ELDN stock under the Base Case scenario is 2.1082 USD.
Compared to the current market price of 4.0677 USD, Eledon Pharmaceuticals Inc is Overvalued by 48%.